Immunohistochemical analysis of the tumor regions revealed low intensity p85 and PCNA expression in p42-AV or two of p42-CTD-AV (183–394 and 280–394 aa) injection groups compared with control vector group (Fig. 7g), suggesting that p42 and its CTD inhibits breast cancer growth in vivo. The gene discussed is PCNA; the disease is breast cancer.